Eisbach Bio

Eisbach Bio is pioneering a novel approach to precision oncology by targeting allosteric regulatory sites on molecular machines essential for tumor genome reorganization. Its core technology, the ALLOS platform, uses physiological screening and proprietary AI models to design highly selective small molecules that exploit synthetic lethal vulnerabilities in genetically defined cancers. The company is advancing a clinical-stage program targeting ALC1 in HRD cancers and has a preclinical pipeline targeting CHD1 and WRN, aiming to create therapies with a wider therapeutic window.

The ALLOS platform integrates physiological screening of full-length enzyme complexes with proprietary, target-specific AI models to discover allosteric small-molecule inhibitors. It focuses on 'Real Biology First,' screening targets in their regulated state to uncover synthetic lethal vulnerabilities for precision oncology.

Eisbach competes in the crowded field of precision oncology and DNA damage response, facing large pharma and biotechs pursuing PARP combinations, WRN inhibition, and other synthetic lethal approaches. Its differentiation hinges on the unique allosteric mechanisms discovered by its ALLOS platform, aiming for superior selectivity.